Frontiers in Pharmacology · 2020 · 46 citations · 34 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyPatient SafetyPharmacovigilanceAdverse Drug Event ReportingAdverse Drug Reaction ReportingDrug SafetyMedication SafetyPharmacoepidemiologySpontaneous Reporting SystemsAdverse Drug Reaction Reporting SystemsDrug Safety ReportingDrug Safety SurveillanceMedication Safety Reporting SystemsReporting Odds RatioSpontaneous Reporting AnalysisSpontaneous Reporting System AnalysisSuspected Adverse Drug Reaction Reporting
BACKGROUND: The use of quinolones has been associated with the development of serious and persistent adverse drug reaction (ADR) mainly affecting muscles, joints and the nervous system. This risk has led the European Medicines Agency (EMA) to endorse some restrictions on the use of this class of antibiotic. Therefore, we performed a study to primary estimate the reporting probability of musculoskeletal, neurological, and psychiatric ADRs among quinolone generations using national data. METHODS: , 2019. Risk factors were classified as "age greater than 60 years," "therapeutic indication," "renal failure," "organ transplantation," "use of corticosteroid," and "history of side effects". Reporting odds ratio (ROR) was computed to evaluate the reporting probability of musculoskeletal, neurological, or psychiatric events among quinolones generations. RESULTS: A total of 87 ICSRs with a quinolone as suspected drug that reported at least one musculoskeletal, neurological, and psychiatric adverse event were identified in the Campania spontaneous reporting system. Forty-nine (56.3%) ICSRs reported risk factors (total risk factors 59). The most reported risk factor was "age greater than 60 years" (69.5%), followed by "therapeutic indication" (16.9%), "renal failure" (5.1%), "organ transplantation" (3.4%), "use of corticosteroid" (3.4%), and "history of side effects" (1.7%). Second-generation quinolones were associated with a lower reporting probability of musculoskeletal (ROR 0.70; 95% CI 0.63-0.79), neurological (ROR 0.81; 95% CI 0.73-0.90), and psychiatric (ROR 0.55; 95% CI 0.44-0.63) ADRs compared to the third generation of quinolones. CONCLUSIONS: Our findings showed that third-generation quinolones were always associated with a higher reporting probability of musculoskeletal, neurological, and psychiatric ADRs compared to the second generation ones. Moreover, we described risk factors in more than half of our cases suggesting that the inappropriate use of quinolones is a phenomenon that may frequently predispose patients to the occurrence of these ADRs.
34
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Quinolones: a comprehensive review.
Catherine M. Oliphant, Gary M. Green · PubMed · 2002 · 451 citations
Women encounter ADRs more often than do men
Y Zopf, Christina Rabe, Antje Neubert et al. · European Journal of Clinical Pharmacology · 2008 · 246 citations